| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| HLA-A*0201 & B2M & EBV LMP1 (YLLEMLWRL) | Biotinylated Human HLA-A*02:01&B2M&EBV LMP1 (YLLEMLWRL) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |   | |||
| HLA-A*0201 & B2M & EBV LMP1 (YLLEMLWRL) | PE-Labeled Human HLA-A*02:01&B2M&EBV LMP1 (YLLEMLWRL) Tetramer Protein | Human | HEK293 | $410.00 25ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| NGM-313 | NGM-313; MK-3655 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatitis; Obesity | Details |
| Fazpilodemab | RG-7992; BFKB-8488A; RO-7040551 | Phase 1 Clinical | Genentech Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Insulin Resistance | Details |
| B-1344 | B-1344 | Phase 1 Clinical | Tasly Biomedical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2 | Details |
